


A.




В





#### FIGURE 2A







### FIGURE 2 CONTINUED







% binding/uptake of Reduced Mannan-FITC by DCs















# Figure 4c











50

200

Forward Scatter


250

100 150 200


**Forward Scatter** 

#### FIGURE 5 CONTINUED

## Mannose-PLL-eGFP (r = 0.75)



### Mannose-PEI-eGFP (r =0.75)



## Degree of toxicity of various carriers




FIGURE 7

## Pilot in vivo study: Proliferation assay






FIGURE 8

## Pilot in vivo study: IFN-gamma ELISPOT




#### FIGURE 9




And the line the Man Theo Theo Theo Lines then the parties


FIGURE 10









PLL-DNA (10ug DNA)




PLL-DNA (50ug DNA)




RedMan-PLL-DNA (10ug DNA)




RedMan-PLL-DNA (50ug DNA)




OxMan-PLL-DNA (10ug DNA)




OxMan-FLL-DNA (50ug DNA)



Mannose-PLL-DNA (10ug DNA)



Mannose-PLL-DNA (50ug DNA)



# Extension in vivo study: ELISPOT

## **ELISPOT PLOT IFN-G**

